An independent informational overview of MEDVi's compounded tirzepatide telehealth program, including regulatory ...
The retrospective case study, which was supported by a research grant from Scripps Clinic Medical Group, included 30 patients who reduced their GLP-1 dose frequency for an average of 36 weeks.
Novo Nordisk stock plunged after CagriSema missed against Eli Lilly’s Zepbound, but new obesity drug data and a low valuation ...
An informational overview of Ivím Health's compounded semaglutide and tirzepatide telehealth program, including GLP-1 ID cost ...
Novo Nordisk's next-gen obesity drug CagriSema failed to match Eli Lilly's Zepbound in a head-to-head trial, sending shares ...
The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.
Novo Nordisk A/S still looks like a buy: oral Wegovy growth, solid global demand, 13x forward P/E, and buybacks support upside. Click for this NVO stock update.
Health and Me on MSN
Zepbound outperforms other weight loss drugs, more details inside
A head-to-head trial showed Eli Lilly’s Zepbound produced 25.5% weight loss versus 23% with Novo Nordisk’s CagriSema, missing noninferiority goals. Findings reshape obesity treatment strategies, ...
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
The FDA has approved a label expansion for tirzepatide (Zepbound; Eli Lilly), allowing use of a 4-dose, single-patient-use KwikPen that delivers a full month of treatment in 1 device for chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results